These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10381513)

  • 1. A high-affinity human antibody that targets tumoral blood vessels.
    Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
    Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
    Demartis S; Tarli L; Borsi L; Zardi L; Neri D
    Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
    Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
    J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
    Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
    Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
    Viti F; Tarli L; Giovannoni L; Zardi L; Neri D
    Cancer Res; 1999 Jan; 59(2):347-52. PubMed ID: 9927045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.
    Rossin R; Berndorff D; Friebe M; Dinkelborg LM; Welch MJ
    J Nucl Med; 2007 Jul; 48(7):1172-9. PubMed ID: 17574989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
    Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
    Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
    Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers.
    Birchler M; Neri G; Tarli L; Halin C; Viti F; Neri D
    J Immunol Methods; 1999 Dec; 231(1-2):239-48. PubMed ID: 10648941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeted delivery of TNFalpha to tumor blood vessels.
    Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
    Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.
    Santimaria M; Moscatelli G; Viale GL; Giovannoni L; Neri G; Viti F; Leprini A; Borsi L; Castellani P; Zardi L; Neri D; Riva P
    Clin Cancer Res; 2003 Feb; 9(2):571-9. PubMed ID: 12576420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.
    Birchler MT; Milisavlijevic D; Pfaltz M; Neri D; Odermatt B; Schmid S; Stoeckli SJ
    Laryngoscope; 2003 Jul; 113(7):1231-7. PubMed ID: 12838025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis.
    Fattorusso R; Pellecchia M; Viti F; Neri P; Neri D; Wüthrich K
    Structure; 1999 Apr; 7(4):381-90. PubMed ID: 10196121
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.